RNA-Based Therapeutics Market Industry Trends: Global Market to Reach USD 47.9 Billion by 2036 at 10.4% CAGR

The global RNA-based therapeutics market reached USD 16.2 billion in 2025 and is projected to reach USD 47.9 billion by 2036, expanding at a CAGR of 10.4% from 2026 to 2036. The market growth is driven by increasing adoption of RNA-based drugs, advances in mRNA and RNA interference technologies, rising investments in precision medicine, and growing demand for innovative treatments for chronic and genetic diseases.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86966

Market Overview

RNA therapeutics are medicines that use ribonucleic acid molecules to treat or prevent disease by influencing the flow of genetic information. Unlike traditional drugs that target proteins downstream, RNA therapies work upstream at the level of genetic messaging. RNA-based therapeutics utilize distinct mechanisms of action to target various biological pathways, offering innovative solutions for a range of diseases.

Analysts' Viewpoint

The advancement of RNA therapies and their different applications in the treatment of genetic disorders, infectious diseases, cancer, and chronic ailments is expected to drive the growth of the RNA-based therapeutic market over the forecast period along with increasing demand for precise and personalized medication. Key RNA therapeutic modalities include mRNA, siRNA, and antisense oligonucleotides, and there have also been extensive improvements in lipid nanoparticles used for delivering RNA. However, some challenges such as the unstable nature of RNA, off-target effects, and difficulties with delivering RNA to specific tissues, high costs, and strict regulations may hinder its success in the market.

The field of RNA therapy is evolving as the development of next-generation RNA medicines targeting various conditions, such as neurological, cardiovascular, metabolic, autoimmune, and oncology diseases. Increasing investments made by pharmaceutical and biotech corporations, more partnerships among companies, and a growing number of scientific collaborations are expected to accelerate RNA therapeutic development. The use of AI in RNA design, advanced bioinformatics, and new approaches to RNA delivery will help improve the outcomes of these projects. The trends observed in this market are connected with the move toward personalized RNA treatments, as well as the growth of self-amplifying RNA and circular RNA technologies.

Analysis of Key Players

The competitive landscape is characterized by proprietary RNA technologies, delivery platforms, clinical pipelines, strategic partnerships, and investments in manufacturing capabilities.

Leading companies operating in the global RNA-based therapeutics market include:

• Alnylam Pharmaceuticals, Inc.
• BioNTech SE
• Ionis Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Silence Therapeutics
• CRISPR Therapeutics
• Pfizer Inc.
• Novartis AG
• AstraZeneca
• Sanofi
• GSK plc.
• Regeneron Pharmaceuticals Inc.
• Wave Life Sciences
• Sirnaomics, Inc.
• Arbutus Biopharma
• Intellia Therapeutics Inc.
• Strand Therapeutics
• Other Prominent Players

Strategic collaborations, licensing agreements, clinical development, RNA delivery innovation, and manufacturing expansion remain key competitive strategies.

Recent Developments (2025-2026)

• In February 2026, Ethris GmbH and the German Center for Infection Research announced a strategic research collaboration to develop mRNA-based vaccines for the prevention and treatment of infectious diseases. The collaboration combines Ethris' proprietary, clinically-validated mRNA technology platforms with DZIF's translational vaccine research expertise spanning a broad spectrum of pathogens, including viruses, bacteria, and parasites.

• In June 2026, Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Recordati, under which Recordati obtained exclusive rights to develop and commercialize zilganersen, an investigational RNA-targeted medicine for Alexander disease (AxD), in all countries outside the U.S. Ionis will maintain sole commercial responsibility for zilganersen in the U.S. and will continue to lead development globally. Recordati will be responsible for regulatory filings and commercialization outside the U.S., including country-specific support for early access pathways based on local regulations and access dynamics.

• In November 2025, Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease, with an estimated 6,500 people in the U.S. living with genetic or clinical FCS, characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis.

👉 Discuss Implications for Your Industry Request Sample Market Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=86966

Key Developments & Trends

• mRNA Therapeutics: Advances in mRNA technology are expanding applications beyond vaccines.

• RNA Interference: siRNA-based therapies are gaining traction for targeted gene-silencing applications.

• Precision Medicine: RNA technologies offer opportunities for highly targeted therapeutic approaches.

• Advanced Delivery Systems: Lipid nanoparticles and other delivery technologies are improving RNA stability and cellular uptake.

• Rare Disease Applications: Growing clinical research is expanding RNA-based treatments for genetic and rare diseases.

Challenges

• RNA Stability: RNA molecules can be susceptible to degradation and require specialized formulation and delivery technologies.

• Delivery Complexity: Efficiently delivering RNA molecules to specific tissues remains a major technical challenge.

• Manufacturing Costs: Large-scale production of high-quality RNA therapeutics can require sophisticated manufacturing infrastructure.

• Regulatory Complexity: Novel RNA platforms require extensive safety, efficacy, and manufacturing evaluation.

Opportunities

• Rare & Genetic Diseases: RNA therapies offer significant potential for treating previously difficult-to-target genetic conditions.

• Oncology: Increasing research into cancer-related RNA targets is creating new therapeutic opportunities.

• Personalized Medicine: RNA platforms can potentially be tailored to specific patient and disease characteristics.

• Next-generation Delivery: Development of tissue-specific and targeted delivery systems can significantly expand applications.

Market Segmentation

By Therapeutic Type

• Messenger RNA (mRNA) Therapeutics
• Small Interfering RNA (siRNA) Therapeutics
• RNA Aptamers and MicroRNAs
• Other RNA-Based Therapeutics (saRNA, circRNA, RNA editing, ribozymes)

By Application

• Infectious Diseases
• Oncology
• Genetic & Rare Diseases
• Neurological Disorders
• Cardiovascular & Metabolic Diseases
• Ophthalmic Disorders
• Autoimmune & Inflammatory Diseases
• Others

By End-user

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Conclusion

The global RNA-based therapeutics market is expected to witness strong growth through 2036, supported by advances in RNA engineering, delivery technologies, precision medicine, and biotechnology research. Expanding applications in rare diseases, oncology, metabolic disorders, and genetic conditions are expected to broaden the market's commercial potential. Continued investments in clinical development, scalable manufacturing, and targeted RNA delivery systems will further shape the industry as RNA-based medicines become an increasingly important component of modern therapeutics.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86966<ype=S

Frequently Asked Questions

• How big was the global RNA-based therapeutics market in 2025?

The market was valued at USD 16.2 Billion in 2025

• What is the projected size of the RNA-based therapeutics market by 2036?

The market is projected to reach USD 47.9 billion by 2036

• What are the factors driving the RNA-based therapeutics market?

Rising prevalence of genetic and rare diseases and rapid advancements in RNA technologies and targeted delivery platforms.

• At what CAGR is the RNA-based therapeutics market expected to grow during the forecast period?

The market is anticipated to expand at a CAGR of 10.4% from 2026 to 2036

• Which region is expected to dominate the RNA-based therapeutics market during the forecast period?

North America is expected to account for the largest market share from 2026 to 2036

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.